Table 4.
Multivariate analysis of distant disease-free survival for the HR+/HER2− pT1pN0 patients, including Ki-67 and risk of recurrence score as continuous and categorical variables
| DDFS (n = 164) | BCSS (n = 171) | |||||
|---|---|---|---|---|---|---|
| Hazard ratio | 95% CI | p Value | Hazard ratio | 95% CI | p Value | |
| Ki-67 and ROR score as continuous variables | ||||||
| Age | ||||||
| < 55 years | 1 | 1 | ||||
| ≥ 55 years | 1.71 | 0.50–5.80 | 0.391 | 1.10 | 0.41–3.00 | 0.849 |
| Grade | ||||||
| I | 1 | 1 | ||||
| II | 1.56 | 0.31–7.99 | 0.591 | 1.87 | 0.48–7.21 | 0.366 |
| III | 1.26 | 0.16–9.86 | 0.827 | 2.25 | 0.40–12.61 | 0.355 |
| Ki-67 | 1.04 | 0.98–1.09 | 0.172 | 1.01 | 0.96–1.06 | 0.729 |
| ROR score | 1.05 | 1.01–1.09 | 0.011 | 1.05 | 1.02–1.08 | 0.002 |
| Ki-67 and ROR score as categorical variables | ||||||
| Age | ||||||
| < 55 years | 1 | 1 | ||||
| ≥ 55 years | 1.36 | 0.44–4.23 | 0.598 | 1.06 | 0.41–2.72 | 0.912 |
| Grade | ||||||
| I | 1 | 1 | ||||
| II | 1.88 | 0.34–10.34 | 0.468 | 2.19 | 0.56–8.55 | 0.258 |
| III | 1.70 | 0.22–13.01 | 0.609 | 2.62 | 0.47–14.50 | 0.271 |
| Ki-67 | ||||||
| < 15% | 1 | 1 | ||||
| 15–30% | 0.62 | 0.12–3.31 | 0.576 | 0.66 | 0.19–2.28 | 0.514 |
| > 30% | 1.94 | 0.33–11.52 | 0.465 | 1.59 | 0.40–6.34 | 0.513 |
| ROR score | ||||||
| Low | 1 | 1 | ||||
| Intermediate | 9.56 | 1.01–90.87 | 0.049 | 4.52 | 1.08–18.85 | 0.038 |
| High | 27.22 | 2.46–300.49 | 0.007 | 9.09 | 1.80–14.50 | 0.008 |
Abbreviations: BCSS Breast cancer-specific survival, DDFS Distant disease-free survival, HER2 Human epidermal growth factor receptor 2, HR Hormone receptor, ROR Risk of recurrence